Chemogenomic Profiling of the Fungal PathogenCandida albicans
ABSTRACT
There is currently a small number of classes of antifungal drugs, and these drugs are known to target a very limited set of cellular functions. We derived a set of approximately 900 nonessential, transactivator-defective disruption strains from the tetracycline-regulated GRACE collection of strains of the fungal pathogen
INTRODUCTION
The interaction between microbes and antimicrobial compounds is of considerable interest for both practical and scientific reasons. The discovery and exploitation of penicillin ushered in the era of well-defined antibacterial molecules (1), and drugs against other human pathogens followed from the initial successes of such antibiotics (2). This has had a revolutionary impact on human health. More recently, the rise of antibiotic resistance among a wide variety of human pathogens has put our medical exploitation of antimicrobial compounds at risk, increasing the interest both in drugs with new modes of action and in defining the mechanisms of resistance to find strategies to circumvent such mechanisms (3).
Eukaryotic pathogens have provided particularly challenging targets for antimicrobial compound development, because the underlying molecular processes controlling growth and proliferation of these pathogens are generally conserved with those of the equivalently eukaryotic human host. Thus, compounds that target central cellular functions in eukaryotic pathogens run the risk of targeting host cells as well, with the potential for serious side effects. Compounds that are clinically successful against eukaryotic pathogens have had to exploit unique features of the pathogens; this has tended to limit the classes of compounds that generate successful drugs to combat these pathogens (4).
A variety of
It is therefore of considerable interest to researchers to identify antifungal drugs with new modes of action, to find new antifungal targets, and to investigate strategies for overcoming resistance to current drugs. Chemogenomics, which can be defined as the high-throughput investigation at the genomic level of the interaction of small molecules with cells (9), provides a potential tool for such studies. In concrete terms, chemogenomic investigations often involve establishing the relationships between what are typically small molecules or collections of small molecules and a genomically defined organism. These relationships can include finding genes whose expression is modulated by the treatment of a cell with the compound or compounds (10), identifying inactivated genes that confer sensitivity or resistance to a specific chemical or library of molecules, or establishing which chemicals interact physically or functionally with a biologically defined target (11, 12). The analysis of the interaction between small molecules and genomically defined cells is particularly promising for the ascomycete fungi. These fungi typically have small genomes, and several species have been investigated extensively through the construction of libraries of inactivated genes.
While the connection of model yeast disruption collections to chemical libraries has provided significant insight into the interactions of various compounds with genetic networks, the interaction of compounds with human-pathogenic fungi is of particular interest. The recent development of the GRACE library, an extensive collection of conditional mutants of
We made a derivative library from the GRACE collection to create a collection of nonconditional, nonessential inactivated genes. We used this library to probe for genes whose inactivation leads to either sensitivity or resistance to a set of commercial or candidate antifungal drugs. Drugs of the same class generated similar profiles of genes conferring sensitivity and resistance, while different drug classes had very distinct profiles. Intriguingly, comparisons with other fungi showed that the gene networks conferring sensitivity to a particular drug can show dramatic differences among species even though the drug target is the same.
RESULTS
Development of a nonconditional derivative collection from the GRACE library.
The GRACE collection of
Echinocandins.
Echinocandins represent an important class of antifungal drugs. These compounds disrupt the cell wall of
Both compounds gave clear sensitivity and resistance profiles, and the overlap in activity between the two compounds was considerable. As shown in Fig. 1A, 149 strains were found to show resistance to caspofungin, 63 strains showed resistance to anidulafungin, and 39 strains showed a common resistance to both compounds. Similarly, the sensitivity profiles of the two compounds had considerable overlap: 158 strains showed sensitivity to caspofungin, 144 strains showed sensitivity to anidulafungin, and 78 strains showed sensitivity in common (Fig. 1B).
A set of 37 of the most sensitive of the 78 commonly sensitive strains were selected and tested at diminishing concentrations of both caspofungin (4 μg/ml, 2 μg/ml, and 1 μg/ml) and anidulafungin (0.1 μg/ml, 0.06 μg/ml, and 0.03 μg/ml). Overall, 19 strains were found to be sensitive to even the lowest drug concentration used for both echinocandins. Of these mutants, 14 showed sensitivity to one or more of the other drugs we tested. The remaining 5 mutated genes thus showed, among the drugs we tested, a specific sensitivity to the echinocandins. They included GSG1, encoding a putative subunit of the TRAPP complex involved in targeting of endoplasmic reticulum (ER)-to-Golgi transport vesicles (29); UBC15, encoding a putative E2 ubiquitin-conjugating enzyme (30); APM3, encoding a phosphorylated protein of unknown function (31) with upregulated transcripts in clinical isolates from HIV-positive patients with oral candidiasis (32); NUP192, which has orthologs encoding components representing a structural constituent of the nuclear pore (33), and MAG2, whose
We determined the 50% inhibitory concentrations (IC50s) of caspofungin and anidulafungin for these mutant strains (Table 1). For both drugs, the sensitive strains showed enhanced IC50 values; the strains showed 40- to 50-fold enhanced sensitivity to caspofungin and 1.5- to 10-fold enhanced sensitivity to anidulafungin.
Drug and strain sensitivity | IC50 (μM) for indicated WT or mutant straina | |||||
---|---|---|---|---|---|---|
Caspofungin | ||||||
Sensitive strains | WT | GSG1 | UBC13 | APM3 | MAG2 | NUP19 |
0.072 | 0.0013 | 0.0015 | 0.0018 | 0.0015 | 0.0015 | |
Resistant strains | WT | DFG5 | GPI12 | MSU1 | ITR1 | ALO1 |
0.072 | 0.24 | 0.23 | 0.25 | 0.18 | 0.33 | |
Anidulafungin | ||||||
Sensitive strains | WT | GSG1 | UBC13 | APM3 | MAG2 | NUP192 |
0.013 | 0.0087 | 0.0077 | 0.0093 | 0.0013 | 0.0083 | |
Resistant strains | WT | DFG5 | GPI12 | MSU1 | ITR1 | ALO1 |
0.013 | 0.023 | 0.017 | 0.025 | 0.02 | 0.013 | |
Fluconazole | ||||||
Sensitive strains | WT | SEC65 | NPY1 | PAA11 | SOG2 | ERG251 |
23 | 12 | 7.2 | 5.4 | 3.7 | 2.2 | |
Resistant strains | WT | ERG3 | HCS1 | SLD1 | RAP1 | ADP1 |
23 | 34 | 30.03 | 32 | 54 | 37 | |
Posaconazole | ||||||
Sensitive strains | WT | SEC65 | NPY1 | PAA11 | SOG2 | ERG251 |
0.13 | 0.099 | 0.1 | 0.1 | 0.085 | 0.089 | |
Resistant strains | WT | ERG3 | HCS1 | SLD1 | RAP1 | ADP1 |
0.13 | 0.27 | 0.37 | 0.24 | 0.25 | 0.24 | |
Amphotericin B | ||||||
Sensitive strains | WT | PDS5 | PCM1 | RPO21 | MNR2 | YAK1 |
0.52 | 0.28 | 0.35 | 0.24 | 0.18 | 0.21 | |
GPI-C107 | ||||||
Sensitive strains | WT | ERG6 | NCP1 | CHS7 | PAT1 | LEM3 |
1.9 | 0.32 | 0.058 | 0.16 | 0.056 | 0.11 | |
Resistant strains | WT | PEX14 | CDC1 | SNG1 | ERP3 | POR1 |
1.9 | 2.9 | 4.1 | 3.7 | 3.4 | 4.7 | |
GPI-Ly7 | ||||||
Sensitive strains | WT | ERG6 | NCP1 | CHS7 | PAT1 | LEM3 |
13 | 2.7 | 2 | 0.93 | 1.7 | 1.2 | |
Resistant strains | WT | PEX14 | CDC1 | SNG1 | ERP3 | POR1 |
13 | 31 | 31 | 64 | 21 | 26 |
aThe values typically fall within the same ranges as those for previously published values for the same drugs (82–86).
Using assays similar to ours, previous studies identified inactivations of genes that caused echinocandin sensitivity. Several of these genes (SSU81, MSB2, VPS28, and CEK1) were also identified in our screen as causing echinocandin sensitivity (but not hypersensitivity) when inactivated. Other genes identified in the literature, such as MID1, MNN1, and RIM101, affected other drug sensitivities as well as caspofungin sensitivity and thus were not uniquely influencing the echinocandin response. However, CDC10, whose deletion specifically caused increased sensitivity to caspofungin (35), was not picked up in our screen, although the mutant is in the GRACE 1.0 collection.
We also tested the 37 most resistant strains among the 39 commonly resistant strains identified in our screen with incrementally increasing concentrations of caspofungin (4 μg/ml, 6 μg/ml, and 8 μg/ml) and anidulafungin (0.1 μg/ml, 0.15 μg/ml, and 0.2 μg/ml). We identified 12 strains that were resistant to even the highest drug concentrations used. Among them, the strains disrupted for CRH11, ADP1, and PCL6 also showed resistance to other drugs, so there were nine strains that showed consistent resistance to both echinocandins but not to the other compounds investigated; five of the most resistant among them were investigated more thoroughly (Fig. 3A and B). These included strains with mutations of DFG5, which encodes an N-linked mannoprotein that is predicted to be a cell wall component; GPI12, whose
We determined the IC50s of both drugs for the wild-type (WT) and mutant strains (Table 1) and found that for both drugs, the IC50 values for the majority of the resistant strains were 2- to 5-fold higher than those for the wild-type strain.
We compared the genes identified in our screen with genes identified in the literature as causing significant resistance to growth in the presence of echinocandins when disrupted. DFG5 had previously been identified as conferring specific caspofungin resistance when inactivated (36). Intriguingly, although we did not identify PGA4 as a gene conferring specific echinocandin resistance in our assay as reported previously (36), we did find the disruption to cause sensitivity to the pyridine amide C107. Since pyridine amides target GPI anchor protein production, this overlap is interesting.
Azoles.
Azoles are another key class of antifungal compounds. In contrast to the echinocandins, which disrupt wall biosynthesis, azoles attack the cell membrane by disrupting the synthesis of ergosterol (37). We investigated the actions of two azoles: fluconazole (Flu), a broad-spectrum azole, and posaconazole (Posa), an expanded-spectrum azole (38). As was also seen with the echinocandins, the profiles of the two azoles showed considerable overlap for both sensitivity and resistance (Fig. 4A and B). We identified 119 strains that were resistant to fluconazole and 101 strains resistant to posaconazole, with an overlap of 43 strains, and we found 81 strains sensitive to fluconazole and 145 strains sensitive to posaconazole, with an overlap of 49 strains.
A set of 37 of the most sensitive of the 49 commonly sensitive strains were selected and tested at diminishing concentrations of both fluconazole (10 μg/ml, 7 μg/ml, and 3 μg/ml) and posaconazole (0.1 μg/ml, 0.07 μg/ml, and 0.03 μg/ml). Overall, 5 strains were found to be sensitive to even the lowest drug concentration used for both azoles. These included strains with mutations of SEC65, encoding a component of the protein-targeting signal recognition particle (SRP); NPY1, encoding a putative NAD+ diphosphatase; ERG251, encoding a C-4 sterol methyl oxidase in the ergosterol pathway; PAA11, encoding a putative polyamine acetyltransferase; and SOG2, encoding a leucine-rich repeat domain-containing protein of the RAM cell wall integrity signaling network. The growth curves for these strains compared to those for the control in the presence of fluconazole and posaconazole are shown in Fig. 5A and B. We also calculated the IC50 values (Table 1) for these strains and found that compared to those for the wild type, the IC50 values were 2- to 3-fold enhanced for fluconazole and 1.2- to 1.5-fold enhanced for posaconazole.
Of the genes reported in the literature whose deletion causes sensitivity to azoles, several are found in the GRACE 1.0 collection. Six of these previously reported genes (SOG2, CCH1, PTC2, BCR1, RPN4, and GZF3) were picked up in our screen. VPS28, which was reported in the literature as causing sensitivity to caspofungin, amphotericin B, and fluconazole upon deletion (39), was observed in our screen to cause sensitivity to caspofungin, amphotericin B, and pyridine amides but not fluconazole. However, SWI4, whose deletion was reported in the literature as giving strong reproducible sensitivity to azoles, was not identified in our screen as conferring azole sensitivity but was seen (40) to cause echinocandin sensitivity.
The 37 most resistant strains among the 43 commonly resistant strains were also tested with incrementally increasing concentrations of fluconazole (10 μg/ml, 15 μg/ml, and 20 μg/ml) and posaconazole (0.1 μg/ml, 0.15 μg/ml, and 0.2 μg/ml). We identified 5 mutant strains that were resistant to even the highest drug concentrations used. Among them were strains with disruptions of ERG3, encoding a C-5 sterol desaturase involved in the ergosterol pathway; HCS1, encoding a putative ATP-dependent 5′-3′ DNA helicase; SLD1, encoding a sphingolipid delta-8 desaturase; RAP1, encoding a multifunctional transcription factor controlling telomeres and ribosomal proteins; and ADP1, the gene for a putative PDR subfamily ABC transporter. The growth curves are shown in Fig. 6A and B.
We next calculated the IC50 values (Table 1) for the genes whose deletion caused resistance and found that for fluconazole, the values changed 1.3- to 1.6-fold, while for posaconazole they changed 1.5- to 3-fold. There are relatively few genes reported in the literature whose deletion causes strong resistance to azoles; all candidates in the literature that are also found in the GRACE 1.0 collection (SCH9, ERG3, and ERG6) were observed in our screen.
Amphotericin B.
Amphotericin B is the most commonly used polyene antifungal drug. Its likely mode of action is to bind to ergosterol in the cell membrane, allowing leakage of cellular components and ultimately leading to the death of the cell. We profiled the spectrum of sensitivity and resistance of strains to this compound; no genes were found to confer convincing resistance to amphotericin B, while genes conferring sensitivity were common, with 268 disruption strains identified as being sensitive to the compound at 0.7 μg/ml and 1.0 μg/ml. We chose 5 strains that were highly sensitive to the drug at 0.7 μg/ml for further study. These strains were inactivated for PCM1/AGM1, encoding a putative phospho-acetylglucosamine mutase; PDS5, the gene for a protein with a predicted role in establishment and maintenance of sister chromatid condensation and cohesion; RPO21, encoding an RNA Pol II component; MNR2, encoding a putative ion transporter; and YAK1, encoding a predicted serine-threonine protein kinase. Growth curves for the supersensitive strains and the CaSS1 WT strain in the presence of AmB over 3.5 days are shown in Fig. 7. We further calculated the IC50 values (Table 1) for the strains with gene deletions that caused sensitivity and found that the IC50 values changed 1.5- to 3.0-fold for the strains tested.
Most of the genes reported in the literature as causing significant sensitivity to amphotericin B upon deletion and that are also in the GRACE 1.0 collection were detected in our screen, including PDK2 (41), BUB2 (41), MET16 (41), TPS1 (42), and CYR1 (43). However, FEN12 (44) was not seen as conferring AmB sensitivity in our assay, but it was found to cause resistance to azoles when disrupted.
Pyridine amide derivatives.
New antifungal drugs are interesting for both scientific and potential commercial purposes. The Nakamoto group reported that the pyridine amide 10b (45) and the 2-aminopyridine E1210 (46) inhibited the function of the Gwt1 protein in the GPI biosynthetic pathway and exhibited good bioactivity against
The set of 58 strains sensitive to both pyridine amide derivatives was selected and tested at diminishing concentrations of both GPI-C107 (0.5 μg/ml and 0.25 μg/ml) and GPI-LY7 (2 μg/ml and 1.5 μg/ml). Five strains were found to be sensitive to even the lowest drug concentration used for both pyridine amide derivatives (Fig. 9A and B), and those strains were deleted for ERG6, NCP1, CHS7, PAT1, and LEM3 (49). ERG6 encodes a delta-(24)-sterol C-methyltransferase involved in the ergosterol biosynthesis pathway. NCP1 encodes an NADPH-cytochrome P450 reductase that acts with Erg11p in sterol 14-alpha-demethylation in ergosterol biosynthesis. CHS7 encodes a key regulator of wild-type chitin synthase III activity (CHS3). PAT1 has orthologs that encode chromatin and mRNA binding activity, and LEM3 encodes a putative cell surface receptor protein. Thus, the genes whose deletion caused high sensitivity seem to come from either the ergosterol synthesis pathway or be involved in the synthesis of the cell wall and chitin.
Furthermore, we calculated IC50 values (Table 1) for the two drugs for the genes whose deletion caused sensitivity and found that for GPI-C107, the IC50 value changed 6- to 34-fold for the strains, while for GPI-LY7, the value changed 5- to 15-fold.
The 20 strains commonly resistant to both pyridine amide derivatives were tested with incrementally increasing concentrations of GPI-C107 (0.5 μg/ml, 1 μg/ml, and 2 μg/ml) and GPI-LY7 (2 μg/ml, 4 μg/ml, and 8 μg/ml). Five strains were found to be resistant to even the highest drug concentration for both pyridine amide derivatives and were defective in PEX14, CDC1, SNG1, ERP3, and POR1 (Fig. 10A and B) (49). PEX14 is an open reading frame (ORF) with orthologs whose products bind to peroxisome matrix targeting signals 1 and 2. CDC1 encodes a putative protein involved in GPI anchor remodeling prior to the attachment of cell wall proteins to beta-1,3-glucan, removing ethanolamine phosphate from the first mannose of the GPI anchor, along with being a lipid phosphatase of the endoplasmic reticulum with roles in DNA repair, actin cytoskeleton organization, and cellular manganese ion homeostasis. SNG1 is an ORF with orthologs encoding plasma membrane-localized products with roles in nucleobase-containing compound transport. ERP3 is an uncharacterized ORF with orthologs encoding Golgi apparatus and endoplasmic reticulum localization functions. POR1 encodes a mitochondrial outer membrane porin present in the detergent-resistant membrane fraction and is a possible lipid raft component. Thus, genes whose deletion causes pyridine amide resistance have wide-ranging functions. When the IC50 values were calculated for the drugs in the mutant strains, the observed values were seen to vary 1.5- to 2.5-fold for both drugs.
Relationships among general resistance genes and general sensitivity genes.
All 4 classes of compounds (azoles, echinocandins, polyenes, and pyridine amides) have different molecular targets, so it was of interest to see if there were classes of genes that were found to be involved in sensitivity or resistance to multiple classes of compounds.
We initially used hierarchical clustering to compare the data sets for all the compounds tested. As shown in Fig. 11, each of the functionally related compounds mapped closely together in the dendrogram. The pyridine amide compounds were clustered distinctly from the other compounds when assessed for both resistance and sensitivity. Interestingly, amphotericin B clustered somewhat with the echinocandins in the sensitivity assay.
We next compared the genes implicated in general resistance to azoles, echinocandins, and the pyridine amide derivatives. No mutations in the set of genes we examined conferred resistance to all classes of drugs, and in fact only two genes, YHB5 (encoding a flavo-hemoglobin-related protein) and PCL7 (encoding a putative cyclin), showed up for more than two classes; mutations in these genes caused resistance to azoles, echinocandins, and the pyridine amide derivatives. There was a small set of genes whose inactivation led to resistance for both echinocandins and azoles; in addition to YHB5 and PCL7, we identified the following six other genes: TLG2, encoding a t-snare protein; CHR11, encoding a GPI-anchored transglycosylase; ORF19.3329, involved in calcium-mediated signaling; ADP1, encoding a putative transporter; ORF19.6185, encoding a candidate pseudouridine glycosidase; and ORF19.6199, encoding a potential DNA helicase. Therefore, overall, the gene sets implicated in drug resistance among the compounds were essentially distinct, consistent with their different cellular targets, and among the genes that were implicated in resistance to more than one drug class, there was no evidence of a specific functional class.
In the case of genes whose inactivation caused drug sensitivity, no genes were identified that conferred a general sensitivity to all the drugs, but several genes were found to cause sensitivity to three classes at the same time. The genes whose inactivation led to sensitivities to the pyridine amide derivatives as well as the echinocandins and amphotericin B included putative cytoskeletal element genes, such as SAC7, MEA1, and MYO1, as well as genes encoding candidate components of intracellular trafficking, such as ORF19.3458, VPS24, and VPS28. Several genes were also implicated in conferring sensitivity to echinocandins and azoles as well as amphotericin B; these genes had very diverse functions and included POR1, encoding a mitochondrial porin; GIG1, encoding a glucosamine-induced product; CCH1, encoding a calcium channel; HRT2, encoding transposition of ty3; BUB2, encoding a checkpoint GAP; ORF19.6152, encoding a mitochondrial protein; and GNP3, encoding a glutamine permease.
Confirmations.
Because of the appearance of unrelated loss-of-heterozygosity (LOH) events in a subset of the GRACE 1.0 library, we tested examples of the sensitive and resistant classes for each drug with the original GRACE strains under tetracycline inactivation conditions. These assays confirmed the sensitivity and resistance profiles for the genes conferring sensitivity or resistance to the echinocandins, pyridine amides, and amphotericin B. However, the combination of tetracycline and azoles was found to give anomalous results—several of the GRACE strains inactivated by tetracycline gave results that were inconsistent with the transactivator-deleted GRACE 1.0 strains (Fig. 12). In these cases, we investigated null mutants of the genes (SOG2, NPY1, and PAA11) to test the behavior of the inactivating mutations. Previous work by others, using
Comparisons with other data sets.
Similar library screens for sensitivity to antifungal drugs have been performed with other fungi. In particular, the comprehensive disruption collection available for the budding yeast
DISCUSSION
The relationship between genes and drugs is important for both academic and practical reasons. In the case of antifungal drugs targeting
In the present study, we investigated the interactions of a set of approximately 900 null mutations of nonessential genes of the fungal pathogen
There are different possible explanations for this observation. One is that the level of functional redundancy varies significantly among the species.
A second mechanism that may lead to different spectra of genes implicated in drug sensitivity or resistance involves the differences in the overall wiring of the response circuits. Large-scale rewiring of transcriptional circuits has occurred between these species (57, 58), and the rewiring of posttranslational modifications can generate major differences in metabolic responses (57, 59, 60). These observations argue that the genetic impact of loss of particular genes may depend in part on their relative importance in the specific circuits that have evolved in each separate fungus. Further work, including the construction of double mutant combinations among the genes conferring drug sensitivity or resistance, will be necessary to map out whether there are related genetic circuits whose critical elements differ between species or whether the entire circuitry is different among the different species.
While we currently have a number of therapeutic interventions for fungal diseases, there is a continuing interest in identifying and characterizing new antifungal drugs. We therefore looked at the patterns of sensitivity and resistance generated by compounds of the pyridine amide class of molecules, which have been proposed to target the biosynthesis of GPI anchors through inhibition of Gwt1 (61), a target distinct from those of the clinically available echinocandins, azoles, and amphotericin B. Pyridine amides have been seen to have good anti-
Somewhat surprisingly, analysis of the genes influencing azole sensitivity and resistance identified members of the ergosterol biosynthetic pathway that had opposing effects on the azole response. Deletion of ERG3 led to azole resistance, and deletion of ERG251/ERG25 caused sensitivity. ERG3 encodes the Δ5,6-desaturase acting late in the ergosterol biosynthesis pathway (63). Erg3p is believed to be responsible for converting tolerated 14-methyl intermediates, which accumulate because of azole inhibition of 14C-lanosterol demethylase, into the toxic sterol 14-methylergosta-8,24(28)-dien-3,6-diol(4,5). Therefore, ERG3 inactivation confers azole resistance because the toxic sterol is not formed in its absence, even though the biosynthetic pathway is inhibited by the presence of the azole.
The explanation for sensitivity generated by deletion of ERG251/ERG25 is less obvious, and in fact, ERG25 deletion in
The finding of no AmB-resistant strains in our study is supported by previous studies, which have also failed to show good candidates for gene inactivations causing AmB resistance (68, 69). The mechanism of action of this macrolide drug has been thought to be binding to ergosterol, the major sterol of the cell membrane, leading to formation of small pores and thus increasing permeability for protons and monovalent cations, such as Na, and depolarization of the membrane (70). However, there is also recent evidence that cell death may not be linked to the formation of these pores and that the primary mechanism of amphotericin B killing is through binding with ergosterol (71–73). There is also evidence of mechanisms involving auto-oxidation and generation of reactive oxygen species (ROS) and free radicals in the cell (74, 75), and it has been speculated that AmB-induced accumulation of ROS can possibly explain the low rate of resistance to AmB. Certainly, if there are many independent pathways for AmB function in fungal killing, it is not surprising that a single gene inactivation is unable to produce a clear resistance phenotype.
An interest in improving antifungal therapies requires that we understand the mechanisms by which current therapies function and how the target can block or bypass these therapies. In this study, we used chemogenomics to investigate the genetic networks in
MATERIALS AND METHODS
Media.
Strains were routinely grown in liquid YPD plus uridine (1% yeast extract, 2% peptone, 2% glucose, and 50 mg/liter uridine) at 30°C; screening was done in 200 μl YPD with specific concentrations of each compound. Fluconazole (Sigma) was added to 10 μg/ml from a 5-mg/ml stock in dimethyl sulfoxide (DMSO). Posaconazole (Sigma) was added to 0.1 μg/ml from a 2-mg/ml stock in methanol. Amphotericin B (MP) was added to 1 μg/ml from a 20-mg/ml stock in DMSO. Caspofungin (a gift from Merck) was added to 4 μg/ml from a 10-mg/ml stock in DMSO. Anidulafungin (a gift from T. Dahms) was added to 0.1 μg/ml from a 10-mg/ml stock in DMSO. GPI-C107 was added to 0.5 μg/ml from a 6.4-mg/ml stock in DMSO. GPI-LY7 was added to 2 μg/ml from a 6.4-mg/ml stock in DMSO. Control growth was done in liquid YPD with the corresponding solvent for each compound but lacking the compound. Liquid transfers to 96-well plates involved 200-μl samples transferred using a Corning multichannel pipette.
Strains and plasmids.
The GRACE library of 2,425 strains and the WT strain for the collection, CaSS1 (20), were obtained from Merck. SN76 (76) was used for the construction of knockout strains, with HIS1 and ARG4 cassettes used for the NPY1 double knockout (KO). Briefly, primers NPY1-S1 and NPY1-S2 (see Table S1 in the supplemental material) were used to PCR amplify the disruption cassettes from plasmids pFA-His1 and pFA-ARG4 (51), respectively, and the PCR products derived from pFA-His1 and pFA-Arg4 (77) were used to transform
The SN148 PAA11 (potential polyamine N-acetyltransferase) double KO strain was constructed using CRISPR, as previously documented (52). Briefly, phosphorylated and annealed PAA11 guide RNA primers (LR182F and LR182R) (Table S1) were ligated to a ciprofloxacin (CIP)-treated, BsmBI-digested pV1093 vector. A mutagenic double-stranded oligonucleotide (LR183F and 183R) was used as a repair DNA. This oligonucleotide is complementary to PAA11 and contains a mutation of the PAM sequence, two premature stop codons (UAA and UAG), and a HindIII restriction site. Standard lithium acetate transformation (78) was done on the SN148 strain (76). Transformants obtained on YPD nourseothricin plates were screened by PCR using primers LR184F and LR184R, followed by HindIII digestion. Correct clones were verified by sequencing. (The genotypes of all
Derivative library construction.
The GRACE 1.0 library for phenotype screening, mating ability identification, and drug target discovery was derived from the initial GRACE library (20) by selection against the URA3 marker that was used to select for integration of the tetracycline transactivator cassette. The GRACE collection strains were inoculated in liquid YPD plus uridine and cultured at 30°C for 2 days. Each culture was then diluted 10−1 in sterile water, and 5-μl aliquots of each original culture and the 10−1 dilution were spotted on SD agar medium with 5-fluoroorotic acid (SD–5-FOA+) separately and cultured at 30°C for 6 days. For each strain, the dilution generating a few single colonies on the plate was identified, and a single colony was recultured in liquid YPD plus uridine for 3 days. The new YPD-plus-uridine culture was then diluted, sequential dilutions (10−1, 10−2, and 10−3) were spotted on YPD-plus-uridine agar and cultured at 30°C for 2 days, and then single colonies were chosen for each strain and tested for the ura− phenotype. Finally, strains that failed to grow on SD−ura medium were collected from the corresponding YPD-plus-uridine agar plates and transferred to liquid YPD plus uridine to prepare the library stock. The original library stock was incubated at 30°C for 2 days and then replicated by robotic plating. After 2 days of incubation at 30°C, the new library stocks were mixed with 80% glycerol to final 20% glycerol-supplemented YPD cultures and were stored at −80°C in 96-well microtiter plates before use. All liquid media used for library construction were placed in 96-well microtiter plates, and all agar media used as described above were placed in rectangular petri dishes.
Library validation.
Candidate strains in 96-well plates were plated on fresh YPD-uridine agar and incubated at 30°C for 2 days. Using a sterile 200-μl pipette tip, a single patch of each strain was transferred to a new well of a 96-well PCR plate, and the cells were dispersed in 25 μl of lysis buffer (12.5 μl of 10× PCR buffer [500 mM KCl, 100 mM Tris-HCl, pH 9.0, 15 mM MgCl2, 1% Triton X-100], 0.5 μl 50× lysis enzyme mix [20 U/μl; 50 mM Tris-HCl, pH 8.4, 100 mM KCl, 50% {vol/vol} glycerol, lyticase {260 U/mg; Sigma}], and 12 μl of MilliQ water) for extraction of DNA. PCR plates were incubated for 1 h at room temperature, and then 100 μl of MilliQ sterile water was added to each well. Plates were placed in a thermal cycler and heated at 95°C for 5 min in order to lyse cells and denature proteins. The PCR plates were then centrifuged at 3,000 rpm for 5 min (1,900 × g) in a Beckman Allegra X-12R centrifuge to pellet cellular debris. To test for the loss of the transactivator module by PCR, we used primers LR135F and LR135R, which amplify a 1.2-kb fragment of the Act1 promoter and the TetRGal4 activator. Ten microliters of DNA extracted as described above and rTaq polymerase were used in 50-μl PCR mixtures (a 10-nmol/ml concentration of each deoxynucleoside triphosphate [dNTP], a 10-nmol/ml concentration of each primer, 5 U/ml rTaq). PCR products were verified using 1% agarose gels.
In the end, we obtained 887 ura3− 5-FOA-resistant strains that had lost the tetracycline transactivator and showed reasonable growth profiles. A list of the strains making up the GRACE 1.0 collection is provided in Table S2 in the supplemental material. We did LOH assays by testing the derivative strains for growth on −His plates and nourseothricin (clonNAT) plates because the 5-FOA selection process can result in a simultaneous loss of the URA3 marker and loss of heterozygosity elsewhere in the genome (79). The two heterozygous markers, HIS1 and the nourseothricin resistance marker, representing the two alleles of each random insertion generating the regulated gene disruption, were tested using SD−His and SD-nourseothricin+ media. Among all the mutants, 18.7% lost the HIS marker, 5.1% became nourseothricin sensitive, and no strains simultaneously lost both the HIS1 and nourseothricin resistance markers. When these events were distributed over the
Drug screens and assays for IC50 determination.
The 887 strains of the GRACE 1.0 collection were arrayed in 17 96-well microtiter plates. The arrangement of the strains was designed to minimize artifacts due to effects of growth on the edges of plates and to provide an independent bar-coded confirmation for each plate. All the edges are occupied by the wild-type parent strain CaSS1, and each plate has a unique bar code for the last 6 inner wells (G6 to G11), consisting of various patterns of CaSS1 and the morphologically distinct mutant dig1/dig1 strain (Fig. S1).
The GRACE 1.0 collection of strains was transferred to 96-well plates for analyses. Cells were inoculated from starting saturated culture plates into 200 μl of YPD by use of a replica pinning tool that transfers 2-μl samples and then by a further transfer from this intermediate dilution to wells containing 200 μl drug to generate a starting density that was an approximately 10−4 dilution of the saturated culture, and the cultures were grown at 30°C in YPD medium without shaking in the presence of the drug of interest for 120 h in initial screens and for 48 to 199 h in retests. The initial drug concentration for each compound was selected as that allowing saturated growth of the control strains after 3 days, while drug-free controls showed saturated growth in less than 2 days. Disruption strains that showed saturated growth before 3 days were designated resistant; strains that failed to grow or showed saturated growth after 4 days were designated sensitive. A semiquantitative scoring scale represented the day that saturated growth was observed, so scores of 1 and 2 represented resistance and those of 5 and 6 represented sensitivity. Each drug-library combination was repeated 3 times, and only strains that showed consistent sensitivity or resistance in all 3 replicates were designated such in the final data sets.
To calculate the IC50s of the various compounds, we used a modified version of the NCCLS M27 broth dilution method (80). Briefly, the sensitive and resistant
Comparisons.
To assess the relationships among different antifungal drugs, a hierarchical cluster analysis based on resistance and sensitivity among
Recent publications (14, 18, 53) have shown the drug susceptibilities of members of gene deletion collections of
GRACE library manipulations.
Selected strains from the GRACE library were tested for sensitivity or resistance to specific compounds. These strains were grown in the presence of 100.0 μg/ml tetracycline to inactivate the gene of interest and then tested for growth in the presence of the compound under study at the concentration used to treat the corresponding strains in the GRACE 1.0 collection.
Supplementary Material
Footnotes
Supplemental material for this article may be found at https://doi.org/10.1128/AAC.02365-17.
ACKNOWLEDGMENTS
This work was supported in part by CIHR grant MOP-42516 and in part by the Merck Quebec Fund. Caspofungin was a gift from Merck, and anidulafungin was a gift from Tanya Dahms, University of Regina.
We thank Merck for making the GRACE strains available to the academic research community.
The funders had no role in the study design, data collection and interpretation, or decision to submit this work for publication.
References
- 1. 1966Antibiotics today. Bull N Y Acad Med42:623–632.[PubMed][Google Scholar]
- 2. 1979Antifungal therapy, 1978. Postgrad Med J55:587–592. doi:.[PubMed][Google Scholar]
- 3. 2015The global threat of antimicrobial resistance: science for intervention. New Microbes New Infect6:22–29. doi:.[PubMed][Google Scholar]
- 4. 2014Antifungal drug development: challenges, unmet clinical needs, and new approaches. Cold Spring Harb Perspect Med4:a019703. doi:.[PubMed][Google Scholar]
- 5. 2012Hidden killers: human fungal infections. Sci Transl Med4:165rv13. doi:.[PubMed][Google Scholar]
- 6. 2004Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis39:309–317. doi:.[PubMed][Google Scholar]
- 7. 2014Elucidating drug resistance in human fungal pathogens. Future Microbiol9:523–542. doi:.[PubMed][Google Scholar]
- 8. 2013Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B. Expert Opin Drug Saf12:881–895. doi:.[PubMed][Google Scholar]
- 9. 2004Chemogenomics: an emerging strategy for rapid target and drug discovery. Nat Rev Genet5:262–275. doi:.[PubMed][Google Scholar]
- 10. 2014Mapping the cellular response to small molecules using chemogenomic fitness signatures. Science344:208–211. doi:.[PubMed][Google Scholar]
- 11. 2005Chemical and biological profiling of an annotated compound library directed to the nuclear receptor family. Curr Top Med Chem5:763–772. doi:.[PubMed][Google Scholar]
- 12. 2013Chemogenomics of allosteric binding sites in GPCRs. Drug Discov Today Technol10:e307–e313. doi:.[PubMed][Google Scholar]
- 13. 2002Functional profiling of the Saccharomyces cerevisiae genome. Nature418:387–391. doi:.[PubMed][Google Scholar]
- 14. 2006Exploring the mode-of-action of bioactive compounds by chemical-genetic profiling in yeast. Cell126:611–625. doi:.[PubMed][Google Scholar]
- 15. 2013Systems-level antimicrobial drug and drug synergy discovery. Nat Chem Biol9:222–231. doi:.[PubMed][Google Scholar]
- 16. 2014The yeast deletion collection: a decade of functional genomics. Genetics197:451–465. doi:.[PubMed][Google Scholar]
- 17. 2013Construction of the first compendium of chemical-genetic profiles in the fission yeast Schizosaccharomyces pombe and comparative compendium approach. Biochem Biophys Res Commun436:613–618. doi:.[PubMed][Google Scholar]
- 18. 2014Systematic phenotyping of a large-scale Candida glabrata deletion collection reveals novel antifungal tolerance genes. PLoS Pathog10:
e1004211 . doi:.[PubMed][Google Scholar] - 19. 2007Essential gene identification and drug target prioritization in Aspergillus fumigatus. PLoS Pathog3:
e24 . doi:.[PubMed][Google Scholar] - 20. 2003Large-scale essential gene identification in Candida albicans and applications to antifungal drug discovery. Mol Microbiol50:167–181. doi:.[PubMed][Google Scholar]
- 21. 2007Mechanism-of-action determination of GMP synthase inhibitors and target validation in Candida albicans and Aspergillus fumigatus. Chem Biol14:1163–1175. doi:.[PubMed][Google Scholar]
- 22. 2009Chemical genetic profiling and characterization of small-molecule compounds that affect the biosynthesis of unsaturated fatty acids in Candida albicans. J Biol Chem284:19754–19764. doi:.[PubMed][Google Scholar]
- 23. 2013Isolation, structure, and biological activity of phaeofungin, a cyclic lipodepsipeptide from a Phaeosphaeria sp. using the genome-wide Candida albicans fitness test. J Nat Prod76:334–345. doi:.[PubMed][Google Scholar]
- 24. 2012Potent synergistic effect of doxycycline with fluconazole against Candida albicans is mediated by interference with iron homeostasis. Antimicrob Agents Chemother56:3785–3796. doi:.[PubMed][Google Scholar]
- 25. 2010Gene annotation and drug target discovery in Candida albicans with a tagged transposon mutant collection. PLoS Pathog6:
e1001140 . doi:.[PubMed][Google Scholar] - 26. 2015Global analysis of fungal morphology exposes mechanisms of host cell escape. Nat Commun6:6741. doi:.[PubMed][Google Scholar]
- 27. 2017Genome-wide functional analysis in Candida albicans. Virulence2017:1–17. doi:.[PubMed][Google Scholar]
- 28. 1997Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-d-glucan synthase inhibitors. Antimicrob Agents Chemother41:2471–2479.[PubMed][Google Scholar]
- 29. 2003Genetic control of chlamydospore formation in Candida albicans. Microbiology149:3629–3637. doi:.[PubMed][Google Scholar]
- 30. 2006A glucose sensor in Candida albicans. Eukaryot Cell5:1726–1737. doi:.[PubMed][Google Scholar]
- 31. 2009Evolution of phosphoregulation: comparison of phosphorylation patterns across yeast species. PLoS Biol7:
e1000134 . doi:.[PubMed][Google Scholar] - 32. 2007In vivo transcript profiling of Candida albicans identifies a gene essential for interepithelial dissemination. Cell Microbiol9:2938–2954. doi:.[PubMed][Google Scholar]
- 33. 2014The Candida Genome Database: the new homology information page highlights protein similarity and phylogeny. Nucleic Acids Res42:D711–D716. doi:.[PubMed][Google Scholar]
- 34. 2015Mechanisms of echinocandin antifungal drug resistance. Ann N Y Acad Sci1354:1–11. doi:.[PubMed][Google Scholar]
- 35. 2010An extensive circuitry for cell wall regulation in Candida albicans. PLoS Pathog6:
e1000752 . doi:.[PubMed][Google Scholar] - 36. 2008Functional analysis of Candida albicans GPI-anchored proteins: roles in cell wall integrity and caspofungin sensitivity. Fungal Genet Biol45:1404–1414. doi:.[PubMed][Google Scholar]
- 37. 2016Antifungals: mechanism of action and drug resistance. Adv Exp Med Biol892:327–349. doi:.[PubMed][Google Scholar]
- 38. 2015Triazole antifungals: a review. Drugs Today (Barc)51:705–718. doi:.[PubMed][Google Scholar]
- 39. 2006Deletions of the endocytic components VPS28 and VPS32 in Candida albicans lead to echinocandin and azole hypersensitivity. Antimicrob Agents Chemother50:3492–3495. doi:.[PubMed][Google Scholar]
- 40. 2010PKC signaling regulates drug resistance of the fungal pathogen Candida albicans via circuitry comprised of Mkc1, calcineurin, and Hsp90. PLoS Pathog6:
e1001069 . doi:.[PubMed][Google Scholar] - 41. 2007Genome-wide fitness test and mechanism-of-action studies of inhibitory compounds in Candida albicans. PLoS Pathog3:
e92 . doi:.[PubMed][Google Scholar] - 42. 2011Amphotericin B induces trehalose synthesis and simultaneously activates an antioxidant enzymatic response in Candida albicans. Biochim Biophys Acta1810:777–783. doi:.[PubMed][Google Scholar]
- 43. 2003Cyclic AMP signaling pathway modulates susceptibility of Candida species and Saccharomyces cerevisiae to antifungal azoles and other sterol biosynthesis inhibitors. Antimicrob Agents Chemother47:3195–3201. doi:.[PubMed][Google Scholar]
- 44. 2014Sphingolipid biosynthetic pathway genes FEN1 and SUR4 modulate amphotericin B resistance. Antimicrob Agents Chemother58:2409–2414. doi:.[PubMed][Google Scholar]
- 45. 2010Synthesis and evaluation of novel antifungal agents—quinoline and pyridine amide derivatives. Bioorg Med Chem Lett20:4624–4626. doi:.[PubMed][Google Scholar]
- 46. 2011In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds. Antimicrob Agents Chemother55:4652–4658. doi:.[PubMed][Google Scholar]
- 47. 2012Inhibiting GPI anchor biosynthesis in fungi stresses the endoplasmic reticulum and enhances immunogenicity. ACS Chem Biol7:1520–1528. doi:.[PubMed][Google Scholar]
- 48. 2017Synthesis and biological evaluation of novel 2-aminonicotinamide derivatives as antifungal agents. ChemMedChem12:319–326. doi:.[PubMed][Google Scholar]
- 49. 2005The Candida Genome Database (CGD), a community resource for Candida albicans gene and protein information. Nucleic Acids Res33:D358–D363. doi:.[PubMed][Google Scholar]
- 50. 2008Role of the RAM network in cell polarity and hyphal morphogenesis in Candida albicans. Mol Biol Cell19:5456–5477. doi:.[PubMed][Google Scholar]
- 51. 2003New modules for PCR-based gene targeting in Candida albicans: rapid and efficient gene targeting using 100 bp of flanking homology region. Yeast20:1339–1347. doi:.[PubMed][Google Scholar]
- 52. 2015A Candida albicans CRISPR system permits genetic engineering of essential genes and gene families. Sci Adv1:
e1500248 . doi:.[PubMed][Google Scholar] - 53. 2011Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole. Mol Syst Biol7:499. doi:.[PubMed][Google Scholar]
- 54. 1997Molecular evidence for an ancient duplication of the entire yeast genome. Nature387:708–713. doi:.[PubMed][Google Scholar]
- 55. 2016The birth of a deadly yeast: tracing the evolutionary emergence of virulence traits in Candida glabrata. FEMS Yeast Res16:fov110. doi:.[PubMed][Google Scholar]
- 56. 2015Genomics and the making of yeast biodiversity. Curr Opin Genet Dev35:100–109. doi:.[PubMed][Google Scholar]
- 57. 2004Rewiring the transcriptional regulatory circuits of cells. Genome Biol5:206. doi:.[PubMed][Google Scholar]
- 58. 2015Metabolic regulation in model ascomycetes—adjusting similar genomes to different lifestyles. Trends Genet31:445–453. doi:.[PubMed][Google Scholar]
- 59. 2010Evolution of transcription networks—lessons from yeasts. Curr Biol20:R746–R753. doi:.[PubMed][Google Scholar]
- 60. 2014Metabolism impacts upon Candida immunogenicity and pathogenicity at multiple levels. Trends Microbiol22:614–622. doi:.[PubMed][Google Scholar]
- 61. 2012E1210, a new broad-spectrum antifungal, suppresses Candida albicans hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis. Antimicrob Agents Chemother56:960–971. doi:.[PubMed][Google Scholar]
- 62. 2008Tetracycline alters drug susceptibility in Candida albicans and other pathogenic fungi. Microbiology154:960–970. doi:.[PubMed][Google Scholar]
- 63. 2005An update on antifungal targets and mechanisms of resistance in Candida albicans. Med Mycol43:285–318. doi:.[PubMed][Google Scholar]
- 64. 1997A yeast sterol auxotroph (erg25) is rescued by addition of azole antifungals and reduced levels of heme. Proc Natl Acad Sci U S A94:11173–11178. doi:.[PubMed][Google Scholar]
- 65. 2000Genome-wide expression patterns in Saccharomyces cerevisiae: comparison of drug treatments and genetic alterations affecting biosynthesis of ergosterol. Antimicrob Agents Chemother44:1255–1265. doi:.[PubMed][Google Scholar]
- 66. 2010Transcriptional response to fluconazole and amphotericin B in Candida albicans biofilms. Res Microbiol161:284–292. doi:.[PubMed][Google Scholar]
- 67. 1996Cloning and characterization of ERG25, the Saccharomyces cerevisiae gene encoding C-4 sterol methyl oxidase. Proc Natl Acad Sci U S A93:186–190. doi:.[PubMed][Google Scholar]
- 68. 2002Amphotericin B: spectrum and resistance. J Antimicrob Chemother49(Suppl 1):S7–S10.[Google Scholar]
- 69. 2008Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact. Clin Infect Dis46:120–128. doi:.[PubMed][Google Scholar]
- 70. 1986How do the polyene macrolide antibiotics affect the cellular membrane properties?Biochim Biophys Acta864:257–304. doi:.[PubMed][Google Scholar]
- 71. 2009Amphotericin B and its new derivatives—mode of action. Curr Drug Metab10:459–469. doi:.[PubMed][Google Scholar]
- 72. 2003Organization of antibiotic amphotericin B in model lipid membranes. A mini review. Cell Mol Biol Lett8:161–170.[PubMed][Google Scholar]
- 73. 2012Amphotericin primarily kills yeast by simply binding ergosterol. Proc Natl Acad Sci U S A109:2234–2239. doi:.[PubMed][Google Scholar]
- 74. 2013The role of oxidative and nitrosative bursts caused by azoles and amphotericin B against the fungal pathogen Cryptococcus gattii. J Antimicrob Chemother68:1801–1811. doi:.[PubMed][Google Scholar]
- 75. 2003Apoptosis induced by environmental stresses and amphotericin B in Candida albicans. Proc Natl Acad Sci U S A100:14327–14332. doi:.[PubMed][Google Scholar]
- 76. 2005Strains and strategies for large-scale gene deletion studies of the diploid human fungal pathogen Candida albicans. Eukaryot Cell4:298–309. doi:.[PubMed][Google Scholar]
- 77. 2006New pFA-cassettes for PCR-based gene manipulation in Candida albicans. J Basic Microbiol46:416–429. doi:.[PubMed][Google Scholar]
- 78. 2003An improved transformation protocol for the human fungal pathogen Candida albicans. Curr Genet42:339–343. doi:.[PubMed][Google Scholar]
- 79. 2009Widespread occurrence of chromosomal aneuploidy following the routine production of Candida albicans mutants. FEMS Yeast Res9:1070–1077. doi:.[PubMed][Google Scholar]
- 80. 2002Comparative evaluation of NCCLS M27-A and EUCAST broth microdilution procedures for antifungal susceptibility testing of Candida species. Antimicrob Agents Chemother46:3644–3647. doi:.[PubMed][Google Scholar]
- 81. 2001PAST: paleontological statistics software package for education and data analysis. Palaeontological Association, London, United Kingdomhttp://palaeo-electronica.org/2001_1/past/issue1_01.htm.
- 82. 2003Influences of methodological variables on susceptibility testing of caspofungin against Candida species and Aspergillus fumigatus. Antimicrob Agents Chemother47:2100–2107. doi:.[PubMed][Google Scholar]
- 83. 2011Detailed comparison of Candida albicans and Candida glabrata biofilms under different conditions and their susceptibility to caspofungin and anidulafungin. J Med Microbiol60:1261–1269. doi:.[PubMed][Google Scholar]
- 84. 1995Antifungal susceptibility testing of yeasts: evaluation of technical variables for test automation. Antimicrob Agents Chemother39:2051–2060. doi:.[PubMed][Google Scholar]
- 85. 2011Multilaboratory testing of two-drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis. Antimicrob Agents Chemother55:1543–1548. doi:.[PubMed][Google Scholar]
- 86. 2016Miltefosine inhibits Candida albicans and non-albicans Candida spp. biofilms and impairs the dispersion of infectious cells. Int J Antimicrob Agents48:512–520. doi:.[PubMed][Google Scholar]